Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 5 of 5 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/15/21
End: 11/09/22
Due: 11/09/23
Phase: N/A
Priority: Normal
Start: 03/01/22
End: 02/03/23
Due: 02/03/24
Phase: N/A
Priority: Normal
Start: 12/20/24
End: 04/30/26
Due: 04/30/27
Phase: N/A
Priority: Normal
Start: 05/27/22
End: 09/24/24
Due: 09/24/25
Phase: N/A
Priority: Normal
Start: 08/01/24
End: 01/13/25
Due: 01/13/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study to Evaluate ARD-101 in Adults With Obesity | NCT05121441 | Aardvark Therapeutics, Inc. | user2@example.com | None | 2021-11-15 | 2022-11-09 | 2023-11-09 | - | - | 2025-07-14 |
| Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery | NCT05215847 | Aardvark Therapeutics, Inc. | user2@example.com | None | 2022-03-01 | 2023-02-03 | 2024-02-03 | - | - | 2025-07-14 |
| ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial | NCT06828861 | Aardvark Therapeutics, Inc. | user2@example.com | None | 2024-12-20 | 2026-04-30 | 2027-04-30 | - | - | 2025-07-14 |
| A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome | NCT05153434 | Aardvark Therapeutics, Inc. | user2@example.com | None | 2022-05-27 | 2024-09-24 | 2025-09-24 | - | - | 2025-07-14 |
| A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder | NCT06126653 | Aardvark Therapeutics, Inc. | user2@example.com | None | 2024-08-01 | 2025-01-13 | 2026-01-13 | - | - | 2025-07-14 |